Clinical trials
Autoimmunity clinical trials
Below are recruiting autoimmunity clinical trials, each written for real people, not researchers. We’re tracking 341 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06946706Recruiting
Bacteria overgrowth in stomach condition study
This study looks at whether people with autoimmune gastritis (a stomach condition) are more likely to have small intestinal bacterial overgrowth (SIBO), which can cause bloating and other symptoms. It uses a simple breath test and questionnaires.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07144462RecruitingEarly Phase 1
Testing a new drug for people with certain autoimmune diseases that have come back or not responded to treatment
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07121777Recruiting
CAR T cell therapy for autoimmune diseases
This study tests a new type of cell therapy (CAR T cells) that targets certain immune cells to treat autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, and systemic sclerosis. It may help people whose disease is not well controlled with standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07118657Recruiting
Vegan diet's effect on gut health in kids with autoimmune hepatitis
This study looks at how a vegan diet changes the bacteria in the gut and how that affects diet and disease in children with autoimmune hepatitis. Healthy children are included as a comparison group.
New Delhi, National Capital Territory of DelhiAges birth–18 years - NCT06964269RecruitingPhase 4
Acthar Gel for dry eye and autoimmune disease
This trial tests a new injectable medicine, Acthar Gel, for moderate to severe dry eye and eye pain linked to autoimmune disease. It aims to see if the drug can relieve these symptoms safely.
Nashville, TennesseeAges 18–85 - NCT07105735RecruitingPhase 1
RN1201 injection for hard-to-treat autoimmune diseases
This study tests an investigational injection called RN1201 for people whose autoimmune disease (like lupus, myasthenia gravis, or immune thrombocytopenia) has not responded to standard therapies. The goal is to see if it can better control the disease.
Nanjing, JiangsuAges 18 years+ - NCT07086976RecruitingPhase 3
Study of oral rilzabrutinib for warm autoimmune hemolytic anemia
This trial tests an oral medication (rilzabrutinib) against a placebo for people with warm autoimmune hemolytic anemia (wAIHA). It aims to see if the drug can help control the disease with fewer side effects than current treatments.
Phoenix, ArizonaAges 18 years+ - NCT07095075RecruitingEarly Phase 1
LUCAR-DKS1 for severe autoimmune diseases
This early-phase trial tests an experimental treatment called LUCAR-DKS1, which uses your own immune cells to target and control severe autoimmune diseases like lupus, vasculitis, and scleroderma that haven't responded to other treatments.
Bengbu, AnhuiAges 18–70 - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07052565Recruiting
CAR-T cell therapy for autoimmune diseases
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
HefeiAges 18 years+ - NCT07037732Recruiting
Monitoring rituximab in autoimmune diseases
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Nice, Alpes MaritimesAges 18 years+ - NCT06993727Recruiting
Autoimmune antibodies before immunotherapy
This study is looking for people about to start immune checkpoint inhibitor therapy to see if certain antibodies are present. It may help understand how the body reacts to this treatment.
BrusselsAges 18 years+ - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06921980Recruiting
Cell therapy and brain function in AIHA
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06900010RecruitingPhase 2
CM336 for Autoimmune Blistering Disease
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
JinanAges 18 years+ - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT05383339Recruiting
Testing blood markers in autoimmune, vasculitis, and autoinflammation
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
Paris, FranceAges 18 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06747156RecruitingEarly Phase 1
mRNA medicine for refractory autoimmune diseases
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06730126RecruitingPhase 2
Soquelitinib for ALPS-FAS-related swelling and low blood counts
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
Bethesda, MarylandAges 16–120 - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT06680037RecruitingPhase 1
Azer-cel therapy for immune-related neurological diseases
This trial is testing an experimental cell therapy called azer-cel for people with certain autoimmune diseases that affect the nervous system. The therapy aims to reduce immune attacks on the body by targeting and removing faulty B cells.
La Jolla, CaliforniaAges 18 years+
Hear when a new Autoimmunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmunity?
- Yes. Clin2 currently lists 341 recruiting autoimmunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.